We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
It’s a common and accepted business practice for venture capital firms to invest in biotech companies, often running those companies until they get to a point where they can be acquired or partnered